PCI Biotech fourth quarter and preliminary full year 2020 results


Oslo (Norway), 24 February 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q4 and preliminary full year 2020 results. Please find enclosed the report and presentation.

*The first Asian patient was enrolled in the RELEASE study in South Korea in October, less than three months after opening of the first study site in Asia. All the nine planned study sites in South Korea and Taiwan have been opened, with initial good screening activity

*Several initiatives have been implemented in the RELEASE study to recoup long-term recruitment projections. Besides going into Asia, the most important initiatives are the protocol amendment made to expand the eligible patient population and the addition of new clinical sites

*A total of 47 RELEASE study sites are open by end-January 2021 across EU, US and Asia and all these sites are operating under the amended protocol

*The second wave of the Covid-19 pandemic is still having a severe impact in many countries, and the full consequences of the pandemic and the recruitment initiatives for the RELEASE study cannot yet be fully established. We are seeing indications of increased screening and enrolment after implementation of the new amended protocol and the opening of Asian sites, although we do not expect to see the full effect of these initiatives until the Covid-19 situation improves

*The company continues to have full focus on enrolment of patients into the RELEASE study. The expected timeline for the planned interim analysis remains in the range from 2H 2022 to 1H 2023

*European patent for treatment of bile duct cancer granted. The patent provides an extended protection of the intended use of fimaChem lasting several years beyond the potential market exclusivity offered by the orphan drug designation

*In November a case report series from the Phase I study was published in Endoscopy International Open, providing detailed descriptions of treatment effects in three select patients at the dose chosen for the RELEASE study

*Successful Phase I vaccination proof of concept study published in high impact immunology journal, demonstrating that fimaVacc enhances the immune response to peptide- and protein based vaccines in healthy volunteers

*In October 2020 PCI Biotech was informed that AstraZeneca elected not to enter into a definitive agreement for the fimaNAc technology. Encouraging preclinical results have been achieved with fimaNAc in this collaboration and the decision not to enter into a definitive agreement is primarily based on a strategic evaluation by AstraZeneca of their current development priorities

*In February 2021 PCI Biotech presented the encouraging mRNA data from this collaboration at the UK based 12th Annual RNA Therapeutics Virtual Conference

2020 in review - expanding and optimising the RELEASE study
The Covid-19 pandemic has affected all aspects of business and life, and accentuated the importance of being adaptive and agile in response to changes. For PCI Biotech, with a global pivotal study open in many of the countries most affected by the pandemic, the greatest impact has been on clinical study progress in the fimaChem programme. The main focus during the year has therefore been on mitigating the effects of the pandemic by both optimising and expanding the pivotal RELEASE study, with the aim to minimise the delays inflicted by the pandemic. The early period of the pandemic was used to analyse eligibility failure logs and review investigator feedback on study design and procedures. The study protocol was thereafter amended, and an optimised protocol implemented during the autumn 2020. The expansion to include new countries and sites have run in parallel and the RELEASE study now spans across 47 sites. The expansion to Asia has shown initial good screening and enrolment. The study communication has also been strengthened, both by the establishment of several online tools, interaction with patient organisations and publication of case reports. We expect to see the full effect of these efforts when the Covid-19 vaccination starts to reduce the effect of the pandemic on the healthcare systems.
The foundation of the fimaVacc programme has been reinforced by the granting of two key patents in the US, providing protection for the combination with two important classes of immunomodulators commonly used in the development of vaccines. The publication of the Phase I results in a high-impact immunology journal was another important fimaVacc milestone. The focus is now on utilising the Phase I results in partnering efforts and planning for clinical proof-of-concept in a disease setting.
The fimaNAc collaboration with AstraZeneca ended in 2020, but it has produced important data for the further development of this platform. The results, which were recently presented at a conference on RNA therapeutics, suggest that the fimaNAc technology provides an appealing intracellular delivery solution for certain applications within this class of therapeutics. The rapid development progress of mRNA-based vaccines against Covid-19 has generated a lot of attention to the potential of this class of drugs and we will now focus our efforts towards the most attractive opportunities.
On the corporate side, the medical and business development areas of the organisation have been further strengthened by the appointment of Dr. Amir Snapir as CMO and Mr. Ludovic Robin as CBO. The organisation will continue to be reinforced as we are pursuing multiple potential business opportunities.

An online presentation in English will be held today, Wednesday 24 February 2021, at 08.30am CET (local time). The presentation can be followed as a live webcast, access through link!/hegnarmedia/20210224_2 or the company’s website under “Investors – Reports and presentations – Webcasts”.

Q&A session
There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console. The presentation will also be presented through a teleconference, mainly facilitated for investors intending to ask questions verbally during the Q&A session.

Dial-in details for teleconference, mainly facilitated for verbal questions during Q&A session:
If you plan to use this facility, please join the event 5-10 minutes prior to the scheduled start time using the dial-in numbers below. A line mediator will provide information on how to ask questions.

Norway +47 2350 0296 / Sweden +46 (0)8 5065 3942 / Denmark +45 35 15 81 21 / United Kingdom +44 (0)330 336 9411 / United States +1 929-477-0402. If your country is not listed, we recommend that you use the dial-in details for UK.

When prompted, provide the confirmation code or event title.

Confirmation Code: 9072639     
Event title: PCI Biotech Q4 conference call

The interim report and the presentation will also be available on and on the company's webpage, from 07:00am (CET) on 24 February 2021.

For further information, please contact:
Ronny Skuggedal, CFO
Mobile: +47 9400 5757

About PCI Biotech         
PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaChem consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

For further information, please visit:
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo                

Forward-looking statements    
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Prosafe SE: Safe Boreas to provide accommodation support at Buzzard27.2.2021 14:07:30 CETPress release

Prosafe has signed a contract with CNOOC Petroleum Europe Limited for the charter of the Safe Boreas to provide gangway connected operations supporting the Buzzard platform complex in the UK sector of the North Sea. The firm duration of the contract commencing mid-April 2021 is 100 days with three 30-day options. The Safe Boreas will perform the gangway connected work scope using dynamic positioning, providing CNOOC Petroleum Europe Limited flexibility in operation. Total value of the contract excluding the option periods is approximately USD 8.5 million. Jesper Kragh Andresen, CEO of Prosafe says: "The Safe Boreas will strive to offer CNOOC the highest level of service. The Safe Boreas has operated extensively in the UKCS and will provide the safest working environment." Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to Stavanger

Mandalay Resources Corporation tillkännager resultatrapporten för fjärde kvartalet och helåret 202027.2.2021 08:53:04 CETPressemelding

TORONTO, Feb. 27, 2021 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) är glada över att tillkännage resultatrapporten för fjärde kvartalet och helåret som slutade den 31 december 2020. Bolagets konsoliderade finansiella resultat för året som slutade 31 december 2020, tillsammans med ledningens diskussion och analys (”MD&A”) för motsvarande period, finns tillgängliga under bolagets profil på och på bolagets webbplats Alla valutor i detta pressmeddelande avser US-dollar om inget annat är angivet. Höjdpunkter för fjärde kvartalet 2020: Intäkter på 45,3 miljoner USD;Justerad EBITDA på 25,3 miljoner USD, tredje högsta kvartalsresultatet i bolagets historia;Konsoliderat nettoresultat på 14,7 miljoner USD eller 0,16 USD per aktie; ochJusterat nettoresultat på 12,1 miljoner USD eller 0,13 USD per aktie. Höjdpunkter för helåret 2020: Intäkter på 179,0 miljoner USD, högsta helårsresultatet sedan 20

Annual financial report 202027.2.2021 08:00:00 CETPress release

FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: Anne Sophie Pijcke, directeur, Annual financial report 2020 Regulated information 27 February 2021 The board of directors of Financière de Tubize has established the 2020 annual financial report. This report is available on the website Dividend received from UCB: € 84,4 million (against € 82.4 million in 2019) Profit of € 81,0 million (against € 80.0 million in 2019)Decrease of outstanding debt from € 86.5 million at 31 December 2019 to € 33,5 million at 31 December 2020. If the general shareholders meeting of 30 April 2021 approves the 2020 annual accounts, including the proposed result appropriation, a dividend of € 0,68 will be payable as from 6th of May 2021 onwards at the offices, seats and branches of BNP Paribas Fortis, in exchange of coupon n° 16. Ex-dividend 4 May 2021 Record date 4 May 2021 Payment date 6 May 2021 In addition, the company Other Lo

Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany26.2.2021 18:30:00 CETPress release

Special approval from German Federal Institute for Drugs and Medical Devices (BfArM) enables home use of a SARS-CoV-2 Rapid Antigen Test using a simple nasal swabThe test will be widely available in pharmacies across Germany Basel, 26 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced it has been granted special approval by the German Federal Institute for Drugs and Medical Devices (BfArM) to offer the SARS-CoV-2 Rapid Antigen Test using a simple nasal swab for patient self-testing in Germany. The test is a reliable rapid test for the qualitative detection of a specific SARS-CoV-2 antigen in nasal swab samples.This rapid antigen test collects the sample from the front area of the nose instead of the nasopharynx, resulting in a simplified and more comfortable sampling procedure. By following simple instructions, patients can perform the test at home with results ready after only 15 minutes. The test will be made available in pharmacies and requires no prescription. The G

Cargotec Corporation: Share Repurchase 26.2.202126.2.2021 17:40:00 CETPress release

CARGOTEC CORPORATIONANNOUNCEMENT26.2.2021CARGOTEC CORPORATION: SHARE REPURCHASE 26.2.2021In the Helsinki Stock ExchangeTrade date26.2.2021Bourse tradeBuyShareCGCBVAmount40,362SharesAverage price/ share43.7441EURTotal cost1,765,599.36EURCargotec Corporation now holds a total of 300 531 sharesincluding the shares repurchased on 26.2.2021On behalf of Cargotec CorporationNordea Bank OyjJanne SarvikiviSami HuttunenFor further information, please contact:Mikko Puolakka, Executive Vice President and CFOtel. +358 20 777 4105Hanna-Maria Heikkinen, Vice President, Investor Relationstel. +358 20 777 Attachment CGCBV_26.2_trades

Leasinvest Real Estate SCA sells the semi-industrial part of the Brixton Business Park in Zaventem26.2.2021 17:40:00 CETPress release

Today the deed has been executed regarding the sale of the semi-industrial part of the Brixton Business Park in Zaventem, as already announced in the latest press release regarding the 2020 annual results. The buyer is an affiliate of Exeter Property Group. Knight Frank acted as the broker in this transaction. The Brixton Business Park comprises 5 semi-industrial buildings with a total area of 18,788 sqm. This divestment is fully in line with the strategy of Leasinvest, which is aimed at selling non-strategic properties and focusing on new sustainable projects. The current favorable market situation enabled a successful sale of this type of property. This divestment also has favorable financial effects: not only does the debt ratio now reduce to the targeted level of less than 55%, the realized capital gain on this transaction has also allowed Leasinvest to expedite the reimbursement of part of our derivatives portfolio, thus further reducing the average financing cost following the ea


INCAP CORPORATION STOCK EXCHANGE RELEASE 26 February 2021 at 5.30 p.m. (EET) THE PURCHASE OF AWS ELECTRONICS GROUP Incap Corporation (the “Company” or “Incap”) announced on 23 January 2020 that it has signed an agreement to acquire the entire share capital of AWS Electronics Group (“AWS”). The group has been included in Incap Group’s reporting as of 23 January 2020. The debt-free purchase price was 13.5 million pounds (then approximately EUR 15.9 million), and the additional purchase price amounted to EUR 0.6 million. The acquisition was financed with a loan of EUR 13 million and paid in cash, with the exception of an instalment of 0.6 million pounds to be paid in Incap shares. A PART OF THE PURCHASE PRICE The Board of Directors of the Company has on 26 February 2021 resolved, that the sellers of AWS will be paid an equivalent of 600,000 pounds in new shares of the Company in a directed share issue with payment (the “Share Issue”). The Share Issue will be consummated on 26 February 202